Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus.

ABSTRACT:

Importance

Nirsevimab, a long-acting monoclonal antibody, demonstrated efficacy against respiratory syncytial virus (RSV)-associated lower respiratory tract infections (LRTI) in clinical trials. Postlicensure monitoring is essential to confirm these benefits in clinical settings.

Objective

To estimate the effectiveness of nirsevimab against medically attended RSV infections in infants and to assess how effectiveness varies by disease severity, dosage, and time since immunization.

Design, setting, and participants

This test-negative case-control study utilized inpatient, outpatient, and emergency department data from the Yale New Haven Health System. Nirsevimab-eligible infants who were tested for RSV using polymerase chain reaction between October 1, 2023, and May 9,

SUBMITTER: Xu H 

PROVIDER: S-EPMC11894488 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature